The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
August 28th 2025
The FDA updated sparsentan's REMS, easing monitoring requirements, enhancing treatment access for IgA nephropathy patients, and supporting kidney function preservation.
FDA Grants Breakthrough Therapy Designation to Rare Blood Disorder Treatment
January 4th 2018Officials with the FDA have granted breakthrough therapy designation to eltrombopag (Promacta, Novartis) for first-line use, in combination with standard immunosuppressive therapy, in patients with severe aplastic anemia.
Read More
Tetraphase Submits NDA for Investigational Drug for Complicated Intra-Abdominal Infections
January 3rd 2018Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).
Read More